|
Advertise About
Live
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%

Zymeworks Wins FDA Approval for Zanidatamab in Biliary Tract Cancer

Health Canada review now accelerated after FDA greenlights Zymeworks' HER2-targeted bispecific antibody for previously treated biliary tract cancer — a niche but high-value oncology segment worth over $1.2 billion USD annually.

Editorial independence
·
Reviewed by editorial team
·
Sources cited & linked
·
Not investment advice
3 min read
· Editorial Policy
an american flag on a white background
Photo by Kelly Sikkema on Unsplash
Key Takeaways
  • FDA granted full approval to Zymeworks’ zanidatamab for HER2-positive biliary tract cancer on November 19, 2026, addressing a ~3,750-patient annual U.S. market.
  • Peak U.S. sales are estimated at $400–$550 million USD, with Jazz Pharmaceuticals sharing ex-U.S. revenue through an existing licensing agreement.
  • Health Canada’s Priority Review is ongoing; a Canadian approval decision is expected in Q2 2027 for an estimated 400–500 eligible domestic patients.
  • ZYME stock surged 38.4% on NASDAQ against a weak XBI (-0.17%) and IBB (-0.76%), with the long-term thesis hinging on Phase 3 gastroesophageal data in H1 2027.

Vancouver-based Zymeworks Inc. (NASDAQ: ZYME; TSX: ZYME) received full FDA approval on November 19, 2026, for zanidatamab (Ziihera) in adults with previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer (BTC). The approval marks a pivotal commercial inflection point for the company and validates its proprietary Azymetric bispecific antibody platform after years of clinical investment.

The Indication and Patient Population

Biliary tract cancer — encompassing cholangiocarcinoma and gallbladder cancer — is a rare but aggressive malignancy with a five-year survival rate below 15%. Approximately 12,000 to 15,000 new BTC cases are diagnosed annually in the United States, with roughly 20–25% classified as HER2-positive, translating to an addressable patient population of approximately 3,000 to 3,750 patients per year in the U.S. alone. Standard second-line options have historically offered median overall survival of under six months, leaving a stark unmet medical need. In the pivotal HERIZON-BTC-01 trial, zanidatamab demonstrated an objective response rate of 41.3% with a median duration of response of 12.9 months — data the FDA’s Oncologic Drugs Advisory Committee called “clinically meaningful.”

Commercial Opportunity and Competitive Landscape

Analysts at SVB Securities and Canaccord Genuity estimate peak annual U.S. sales for zanidatamab in BTC of approximately $400–$550 million USD ($572–$787 million CAD at the current rate of 1.4305), with ex-U.S. revenues — including a substantial royalty stream from licensing partner Jazz Pharmaceuticals — potentially adding another $200–$300 million USD. The global BTC therapeutics market is currently valued at approximately $1.2 billion USD and is projected to exceed $2.8 billion USD by 2032, driven by HER2-targeted and FGFR-inhibitor therapies. Competitive pressure exists from Eli Lilly’s trastuzumab deruxtecan (Enhertu), which carries a broad HER2 label, but zanidatamab’s bispecific mechanism — simultaneously targeting HER2 domains ECD4 and ECD2 — offers a differentiated profile that may limit cross-label substitution.

Health Canada granted zanidatamab Priority Review designation in September 2026, and Zymeworks confirmed today that the FDA approval package will be submitted to Health Canada under the existing rolling review. A Canadian approval decision is anticipated in Q2 2027, which would open access to an estimated 400–500 eligible Canadian BTC patients annually.

Stock Reaction and Long-Term Thesis

ZYME shares surged 38.4% on the NASDAQ in early Thursday trading, reaching $21.14 USD ($30.24 CAD), their highest level since January 2024. On the TSX, the stock tracked closely, rising 37.9% to $30.18 CAD on volume of approximately 4.1 million shares — roughly 11 times the 30-day average. The broader biotech tape was soft, with the XBI falling 0.17% to $145.04 and the IBB declining 0.76% to $205.39, underscoring that ZYME’s move was entirely thesis-driven rather than sector-led.

For long-term investors, the approval transforms Zymeworks from a development-stage company into a commercial-stage biopharma with a royalty-generating partnership and a pipeline that includes zanidatamab in gastroesophageal adenocarcinoma (Phase 3 HERIZON-GEA-01 readout expected H1 2027) and ZW171, a mesothelin-targeting bispecific entering Phase 1. The BTC label is narrow but profitable — and if the GEA data deliver, the total addressable market expands by an order of magnitude. The key risk remains cash runway: Zymeworks reported C$310 million in cash and equivalents as of Q3 2026, which management projects covers operations into mid-2028, providing a credible bridge to potential GEA approval.

Metric Detail
Drug / Brand Name Zanidatamab / Ziihera
Indication HER2+ biliary tract cancer (2nd line+)
Regulatory Outcome FDA Full Approval — Nov. 19, 2026
Peak U.S. Sales Estimate $400–$550M USD ($572–$787M CAD)
Partner Jazz Pharmaceuticals (ex-U.S. rights)
ZYME Stock Reaction (NASDAQ) +38.4% to $21.14 USD

James Okonkwo

Boreal Markets Staff

Contributing writer at Boreal Markets.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Boreal Markets and SmallCap Communications Inc. are not registered investment advisers. Always conduct your own due diligence before making investment decisions.

The Boreal Brief

Canadian markets intelligence every morning before the open. Free.